Patent ID: 8043856
Filing Date: 2011-10-25
Classification: A61K,C07K,C12N

Abstract:
1. An isolated host cell infected with a plurality of helper-free recombinant adenovirus vectors effective for infectious influenza virus production, wherein the adenovirus vectors include adenovirus vectors for influenza virus vRNA production and adenovirus vectors for influenza virus mRNA production, wherein (a) the vectors for influenza vRNA production comprise an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB1 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB2 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus HA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NP DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus M DNA linked to a PolI transcription termination sequence, and an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NS DNA linked to a PolI transcription termination sequence; and wherein the adenovirus vectors for mRNA production comprise an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PA, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB1, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB2, and an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus NP; (b) the vectors for influenza vRNA production comprise an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB1 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB2 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus HA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NP DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NA and NB DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus M DNA linked to a PolI transcription termination sequence, and an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NS DNA linked to a PolI transcription termination sequence; and wherein the vectors for mRNA production comprise an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PA, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB1, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB2, and an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus NP; or (c) the vectors for influenza vRNA production comprise an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB1 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus PB2 DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus HA DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NP DNA linked to a PolI transcription termination sequence, an adenovirus vector comprising a PolI promoter operably linked to an influenza virus M DNA linked to a PolI transcription termination sequence, and an adenovirus vector comprising a PolI promoter operably linked to an influenza virus NS DNA linked to a PolI transcription termination sequence; wherein the adenovirus vectors for mRNA production comprise an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PA, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB1, an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus PB2, and an adenovirus vector comprising a PolII promoter operably linked to a DNA segment encoding influenza virus NP; wherein the host cell with the vectors in (c) does not include sequences corresponding to influenza virus NA coding or noncoding sequences for vRNA production or for vRNA production and mRNA NA production.